At UCB, everything we do starts with one simple question: “How will this make a difference in the lives of people living with severe diseases?” This question is our motivation, inspiration and what challenges us to stay focused on what will ultimately benefit the patients we serve. Read more from Camille Lee, Head of U.S. Immunology, about how UCB is working to empower patients impacted by immuno-dermatological conditions.

'Our team has a rich history of transforming science into life-changing medicines for patients within the immunology and neurology communities. As UCB approaches a century of innovation, our commitment to patients has never been stronger. Recently, we have been focused on expanding our patient-first approach to help patients with immuno-dermatological conditions.

Although this year’s American Academic of Dermatology (AAD) Annual Meeting was cancelled, we have the opportunity to connect virtually to advance the discussion, understanding and treatment of dermatological conditions. It will take this shared commitment from across the healthcare community to drive dermatology forward. I’m proud of the research UCB is carrying out right now in immuno-dermatology, and how significant the impact could be for patients in the future.

Psoriasis is one of the most common autoimmune disorders, affecting more than seven million people in the U.S. with significant symptoms such as thick, silvery scales and itchy, dry red patches of skin. Beyond the physical impact, we know that psoriasis can have a negative impact on psychological and social well-being. Keeping the patient experience in mind, our team at UCB is working around the clock to research and develop viable, differentiated treatment options for people with psoriasis who may be accepting the “status quo” – or medicines that may not be entirely fulfilling their needs.

Empowering patients to manage their condition and live life to the fullest is my personal motivation, and one of the reasons I joined UCB. I am confident that with this shared mindset, UCB can deliver value and make a difference to the lives of patients suffering with severe chronic immunologic diseases such as psoriasis.' 


US-P-DA—2000032